Tagged with M&A

USA David H. Crean, PhD, Managing Director for Objective Capital Partners, a leading investment banking advisory firm examines the venture investment activity in life sciences for the past year.    In order to have a successful life sciences R&D program, biotech and pharma companies must develop game-changing therapeutics, companion diagnostics and personalized…

Opinion Christoph Bieri, PhD is Managing Partner of Kurmann Partners, an M&A firm advising Pharma and MedTech companies on strategic mid-market deals in Europe and the Americas. Here he looks at Novartis’ bold M&A moves and what they could mean for their generics arm, Sandoz.   Besides the large business platform…

Japan Takeda’s proposed acquisition of Shire may have come as a surprise to many commentators, but the appointment of an audacious French CEO in the form of Christophe Weber had already set the tone for the radical transformation upon which the Japanese company has embarked in its dual quest for internationalisation…

USA David H. Crean, PhD, Managing Director for Objective Capital Partners, a leading investment banking advisory firm examines the healthcare market for 2018.     Following a decade high of VC invested in 2017, and on a record pace again in 2018, valuations continue to move higher across all stages within…

Spain Following Bayer’s acquisition of Monsanto, a US agriculture giant, the company is facing a new era in which its pharmaceutical arm is still a highly strategic part. Bernardo Kanahuati, Bayer’s CEO for Iberia, highlights the importance of Spain’s manufacturing and R&D for Bayer International, as well as his strategy to…

M&A It has been a robust first half in 2018 within the life sciences sector for mergers and acquisition (M&A) and investment activities. Deal-tracking sources demonstrate M&A values witnessed meaningful increases in Q2 2018, with deal volumes in the quarter reminiscent of 2016 and 2017 levels [1]. I and others [234] continue…

regulation The stakes are high, and the outcome is uncertain in one of the largest Pharma M&A deals ever. Takeda’s proposed acquisition of Shire seems to have it all: The combined entity becoming one of the largest global Pharma groups, enabling Takeda to become a truly global operation and allowing Shire’s…

UK As all eyes are on Takeda these days after its announced acquisition of Shire, Jon Neal, managing director of the UK and Ireland operations of the Japanese player, looks back on the company’s internationalisation path. He further highlights the extremely collaborative approach Takeda engages in with NICE and gives tips…

Pharma The last few years have witnessed the advent of a highly disruptive business model within the heart of the pharma world that fundamentally reconsiders the manner in which R&D is conducted and, as such, we have seen the rise (and sometimes fall) of a new breed of companies that some…

USA Blue-chip drug makers holding USD 200 billion in cash, mostly overseas, will start investing more of it in mergers and acquisitions (M&A) after President Trump’s tax overhaul slashed the cost of spending the money in the US, debt-ratings firm Moody’s predicts. The ratings firm names Amgen, Pfizer, Gilead, and Celgene…

USA Tech giant Amazon’s acquisition of online pharmacy PillPack has caused the stock prices of rival healthcare distributors in the US to fall dramatically. With this move, Amazon has signalled its intent to move into the medical distribution arena and promises to seriously disrupt the way the industry operates. “This acquisition…

Pharma Digital health startups raised over USD six billion in equity financing in 2016, representing a five-year compound annual growth rate of 32 percent and the fledgling industry segment already boasts at least eight unicorns with a combined value exceeding USD 15 billion. Most interesting of all, however, is the constellation…